To conclude, despite the difficulties encountered in the development of miRNA therapeutics, their use in the clinical setting still arouses interest, and synergistic treatments with miRNAs and CFTR modulators for CF patients that do not sufficiently respond to the approved therapies have been suggested [149]. This evidence concerns the gene CFTR and cystic fibrosis.